Lumito (LUMITO) Life Science Summit 2025 summary

Purpose and market need

• Focus on advancing healthcare through improved tissue diagnostics, addressing subjectivity and human error in current analysis methods.

• Solution increases objectivity and quantification in tissue analysis using nanoparticle technology.

• Digital pathology enables global collaboration and mitigates the shortage of trained pathologists.

Technology and product features

• Biomarker detection system offers precise, quantifiable results and visualizes exact biomarker locations in tissue.

• Plug-and-play reagent kit and scanner integrate seamlessly into existing workflows.

• Nanoparticles provide superior stability, biocompatibility, and manufacturability, protected by strong IP.

• Compatible with commercial and proprietary software for image analysis.

Commercialization and business model

• Addressable global market is $1.8 billion, with a European focus on a $470 million segment and a 3-5% target share.

• Business model includes recurring (kits, services) and non-recurring (hardware) revenue streams.

• Early commercialization with reference customers, notably a UK-based CRO now offering the solution.

• Leveraging CROs for scalable reach and awareness, with over 300 relevant CROs identified globally.